Alternatives to Animal Testing in the Quality Control of Immunobiologicals: Current Status and Future Prospects

National Institute of Public Health and Environmental Protection (RIVMJ, P.O. Box 1, 3720 BA Bilthoven, The Netherlands; Bayer AG, PF-Zentrum Mannheim, D-51368 Leverkusen, Germany; 5Bacterial Vaccine Department, Statens Seruminstitut, Artillerivej 5, DK-2300 Copenhagen S, Denmark; Institute of Virology and Immunoprophylaxis, P.O. Box3147, Mittelhausern, Switzerland; 7EuropeanPharmacopoeia Commission, B.P. 907,F -67029 Strasbourg Cedex 1 ,France; 8PaulEhrlichinstitut, P.O. Box 1740, D-63207 Langen, Germany; 9 Afd. Biologische Standaardisatie, Ministerie van Hygiene en Epidemiologie, Juliette Wytmanstraat 14, B-1050 Brussels, Belgium; Coordination Vaccins, Agence du Medicament, Direction des Laboratoires et des Controles, Unite Pharmacologie-Toxicologie, 14 rue Ecole de Pharmacie, 3400 Montpellier, France; liWorldHealth Organisation-Biologicals, CH -1211 Geneva27, Switzerland; Division of Virology, National Institute for Biological Standards and Control (NIBSC), Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK; Rh6ne Merieux, LaboratoireiFFA,254 rue Marcel Merieux, BP 7009, F -69007 Lyon, France; Galenica, Microbiology and Hygiene, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, Belgium; Behringwerke AG, Biological Research, P.O. Box 1140, D-35001 Marburgan der Lahn, Germany; Intervetinc., 405 State Street, P.O. Box 318, Millsboro, DE 19966, USA; FRAME, Russell & Burch House, 96-98 North Sherwood Street, Nottingham NG1 4EE, UK; Istituto Superiore di Sanita, Laboratorio di Medecina Veterinaria, Viale ReginaElena299, I-00161 Rome, Italy; IntervetinternationalB. V., W. de Korvestraat 35, 5831 AN Boxmeer, The Netherlands.